After being diagnosed with metastatic #melanoma, Sharon immediately had surgery to remove the #cancer. Unfortunately, this failed to stop her cancer from spreading. Today, she shares how she found hope through #clinicaltrial research. Listen to her story: https://oncosec.com/patients/
In Dr. Kristen Mueller’s latest article for @MelanomaReAlli, she explored the advantages of #intratumoral therapies and cytokine-based approaches, including our lead product candidate #TAVO™. Read the full article here: https://www.curemelanoma.org/blog/article/clinical-trials-to-watch-intralesional-therapies-for-melanoma
Our primary technology, #TAVOᵀᴹ, has the potential to become the first marketed therapeutic to address the unmet need of anti-PD-1 non-responders. TAVO is administered into the #tumor through electroporation (EP). Learn more about how TAVO and EP works: https://oncosec.com/tavo/
We recently sat down with Fran, Sharon and Julie to discuss their personal experiences using our #electroporation (EP) gene delivery system, which employs a series of momentary energy pulses. Learn about electroporation from a patient’s point of view: https://oncosec.com/patients/
